Polyclonal antilymphocyte/antithymocyte globulin that depletes T cells.
Polyclonal anti–T-lymphocyte immunoglobulin that binds multiple T‑cell surface antigens and induces complement-dependent cytotoxicity and Fc-mediated clearance (ADCC/phagocytosis), leading to rapid T‑cell depletion and immunosuppression.
YES
DIRECT
ATG antibodies bind CD4 on T cells and trigger complement-dependent lysis and Fc-mediated ADCC/phagocytic clearance, depleting CD4+ cells.
Polyclonal antilymphocyte/antithymocyte globulin that depletes T cells.
Polyclonal anti–T-lymphocyte immunoglobulin that binds multiple T‑cell surface antigens and induces complement-dependent cytotoxicity and Fc-mediated clearance (ADCC/phagocytosis), leading to rapid T‑cell depletion and immunosuppression.
YES
DIRECT
ATG antibodies bind CD8α on T cells and induce complement-dependent lysis and Fc-mediated ADCC/phagocytic clearance, depleting the CD8+ T cells.
Polyclonal antilymphocyte/antithymocyte globulin that depletes T cells.
Polyclonal anti–T-lymphocyte immunoglobulin that binds multiple T‑cell surface antigens and induces complement-dependent cytotoxicity and Fc-mediated clearance (ADCC/phagocytosis), leading to rapid T‑cell depletion and immunosuppression.
YES
DIRECT
ATG antibodies bind CD25 on T cells, triggering complement-dependent lysis and Fc-mediated effector functions (ADCC/phagocytosis) that deplete the bound cells.
Autologous cellular immunotherapy using ex vivo–generated dendritic cells pulsed with patient-specific tumor neoantigen peptides to prime/expand neoantigen-specific CD8+ and CD4+ T cells.
Autologous dendritic cells are generated ex vivo and pulsed with patient-specific tumor neoantigen peptides. After infusion, the DCs migrate to lymphoid tissues and present these neoantigens on HLA class I and II, providing costimulation (e.g., CD80/CD86) and cytokines to prime and expand neoantigen-specific CD8+ cytotoxic T cells and CD4+ helper T cells, thereby promoting tumor-specific immune responses and immunologic memory.
YES
INDIRECT
Vaccinated dendritic cells prime/expand neoantigen-specific CD8+ T cells, which then recognize the neoantigen peptide–HLA I on tumor cells and kill them via TCR-mediated cytotoxicity (perforin/granzyme, Fas–FasL).
Polyclonal antilymphocyte/antithymocyte globulin that depletes T cells.
Polyclonal anti–T-lymphocyte immunoglobulin that binds multiple T‑cell surface antigens and induces complement-dependent cytotoxicity and Fc-mediated clearance (ADCC/phagocytosis), leading to rapid T‑cell depletion and immunosuppression.
YES
DIRECT
ATG contains antibodies that bind CD11a (LFA-1) on T cells, triggering complement-dependent lysis and Fc receptor–mediated ADCC/phagocytosis, leading to direct depletion of target-expressing cells.